47 The Drug Rediscovery Protocol Extended Data Table 2. Opened cohorts (continued) Treatment Cohorts (incl. tumor type, tumor profile, and number of evaluable/enrolled patients) Nilotinib GIST KITmut 7/8 GIST PDGFRαmut 1/1 Mesothelioma PDGFRαmut 1/1 Nivolumab All HML>450 15/16 All* MSI 29/30 Olaparib All ATMmut 7/8 All BRCA1/2mut 11/12 All HRRdef 2/2 Pre-specified HRRdef 3/3 Panitumumab Carcinosarcoma RAF/RASwt 1/1 Cervical RAF/RASwt 1/1 GBM RAF/RASwt 1/1 HNSCC RAF/RASwt 1/1 Melanoma RAF/RASwt 1/1 Meningeoma RAF/RASwt 1/1 NSCLC EGFRmut RAF/RASwt 1/1 Salivary RAF/RASwt 1/1 Sarcoma RAF/RASwt 3/3 Thyroid RAF/RASwt 1/1 Pembrolizumab All HML>290 4/7 Breast HML140-290 4/4 CRC* HML140-290 8/10 HNSCC HML140-290 2/3 Prostate HML140-290 1/1 Stomach/esoph. HML140-290 3/4 Other HML140-290 3/4 Regorafenib Esthesioneurobl. RETfus 1/1 NSCLC RETfus 5/7 Melanoma KITmut 1/1 Sunitinib Thymus KITmut 1/1 Prostate PDGFRαmut 1/1 2
RkJQdWJsaXNoZXIy MTk4NDMw